AI in Biotech Research: Boon or Bane?
Philip Crowley
November 29, 2024
Is Artificial Intelligence a Boon Or a Bane? Just a few years ago, discussions about artificial intelligence (“AI”) were mostly
Is Artificial Intelligence a Boon Or a Bane? Just a few years ago, discussions about artificial intelligence (“AI”) were mostly
How AI Is Shaping Life Sciences: Challenges, Risks and Future Prospects Artificial intelligence (“AI”) has become a buzzword—almost every article,
Cybersecurity Challenges in Biotech: Why Your Data is a Prime Target In the first quarter of 2024, weekly cyberattacks against
Shaping Tomorrow: Trends in Biopharmaceutical Manufacturing & FDA Innovations We recently attended an insightful seminar on biotech manufacturing that we’d
The Rise of AI in Life Sciences: Potential and Real Risks Artificial intelligence (AI) is a hot topic. Every article,
Understanding RSV: A Danger to Our Most Vulnerable Populations Great news for the prevention of respiratory syncytial virus (“RSV”) infections!
Here’s a great opportunity for those interested in biomedical research and entrepreneurship. The Biomedical Engineering Department at Stevens Institute of Technology
Orphan drug development is a crucial and complex area of pharmaceutical research. It’s dedicated to creating treatments for rare diseases.
We live in an extraordinary time. It’s a time where technology in life sciences is peeling back the curtain on
A new investigational therapy from Celldex Therapeutics Inc. in Hampton, New Jersey provides the promise of substantial relief from “hives”,
The Impact of Real-World Evidence (RWE) on Drug Testing & FDA Approval The landscape of drug development is undergoing a
There’s no stopping Mother Nature when she gets going. The striking force of a tornado recently tore through a Pfizer
When AI Moves Faster Than the Law Artificial intelligence has fundamentally changed the speed of discovery in the life sciences
Navigating the Shifting Landscape of Drug Pricing for Biotech Companies The landscape of federal drug pricing is undergoing a fundamental
Improvements to New York Health Insurance: Biomarker Testing Testing for biomarkers in patients is the state of the art in
The Real Challenges Behind Patient Support Programs Modern medicine advances through laboratory breakthroughs, but for organizations bringing these therapies to
Protecting Your Growth in a Regulated Market As a New Jersey life sciences founder, you’re likely balancing scientific breakthroughs with
Parkinson’s Disease and Current Diagnostic Challenges For decades, the parkinson’s disease diagnosis relied primarily on identifying clinical symptoms. Doctors traditionally
Last week I had the opportunity to attend the BioMedical Engineering Day at Stevens Institute of Technology in Hoboken, New Jersey. It
Global Cyber Threats Are Now Targeting Medical Devices A hostile, controlling government launches a coordinated ransomware attack on computers across
Demystifying the FDA Investigational Device Exemption (IDE) Process The journey to bring a new medical device to market is a
Why the IND Process Matters Drug sponsors face a long and winding road from discovery to market. A critical step
Patents For Humanity Program Improvement Act The Patents for Humanity Program Improvement Act, H.R. 7259, was introduced on June 18th,
According to the National Institutes of Health (NIH), there are over 7,000 diseases classified as rare, affecting an estimated 25-30 million Americans.
What You Need to Know to Get Approved Bringing a new drug therapy or medical device to market is a